VAXCYTE INC. - COMMON STOCK

Vaxcyte to Present at the Jefferies Healthcare Conference

02 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

09 May 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte to Participate in Upcoming Investor Conferences in May

03 May 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

05 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

04 Apr 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

28 Feb 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

23 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

17 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $100 Million Public Offering

13 Jan 2022 01:07:31 By Nasdaq GlobeNewswire

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Jan 2022 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

06 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at Upcoming Investor Conferences

11 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

10 Nov 2021 16:10:00 By Nasdaq GlobeNewswire

Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

28 Oct 2021 08:30:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

28 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

21 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

20 Sep 2021 16:30:00 By Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

11 Aug 2021 16:07:45 By Nasdaq GlobeNewswire

Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections

05 Aug 2021 08:30:01 By Nasdaq GlobeNewswire